ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,179.68
-0.55%
Dow Jones
39,164.06
0.09%
Gold vs US Dollar
2,320.35
-0.32%
Brent Oil
85.505
0.11%
Bitcoin
62,060.24
0.73%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Rxi Pharmaceuticals Corp. (MM) (RXII)

  7. Rxi Pharmaceuticals Corp. (MM) (RXII) News

RXI Pharmaceuticals Corporation (RXII)

Rxi Pharmaceuticals Corp. (MM)
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:RXII
DateTimeSourceHeadlineSymbolCompany
15/02/201912:15PR Newswire (US)Phio Pharmaceuticals Appoints Gerrit Dispersyn as New Chief Executive Officer Effective March 1NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
10/12/201814:35Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
26/11/201814:30Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
19/11/201822:52Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
14/11/201812:12Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
14/11/201812:10PR Newswire (US)RXi Pharmaceuticals Reports Third Quarter 2018 Financial Results and Recent Corporate HighlightsNASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
14/11/201812:08Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
13/11/201822:31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
13/11/201814:26Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
07/11/201812:05PR Newswire (US)RXi Pharmaceuticals to Present New Data Demonstrating the Ability of sd-rxRNA to Enhance NK Cell Activity for Adoptive Cell T...NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
06/11/201812:05PR Newswire (US)RXi Pharmaceuticals to Webcast Third Quarter 2018 Financial Results on Wednesday, November 14, 2018NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
29/10/201813:28Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
15/10/201814:26Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
10/10/201819:00Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
05/10/201822:04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
03/10/201821:31PR Newswire (US)RXi Pharmaceuticals Announces Closing Of $15 Million Underwritten Public OfferingNASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
02/10/201822:32Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(4) (424b4)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
02/10/201822:30Edgar (US Regulatory)Post-effective Amendment Filed Solely to Add Exhibits to a Registration Statement (pos Ex)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
01/10/201817:42Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
01/10/201811:39Edgar (US Regulatory)Registration of Additional Securities (up to 20%) (s-1mef)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
01/10/201811:36Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
01/10/201811:10PR Newswire (US)RXi Pharmaceuticals Announces Pricing Of $15 Million Upsized Underwritten Public OfferingNASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
28/09/201811:14Edgar (US Regulatory)Securities Registration Statement (s-1/a)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
26/09/201813:01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
26/09/201813:00PR Newswire (US)RXi Pharmaceuticals to Present New Data from its Immuno-Oncology Program Using sd-rxRNA Therapeutic Compounds Targeting Intra...NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
14/09/201822:48Edgar (US Regulatory)Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
14/09/201822:48Edgar (US Regulatory)Securities Registration Statement (s-1/a)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
04/09/201812:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
31/08/201822:32Edgar (US Regulatory)Securities Registration Statement (s-1)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
28/08/201814:15PR Newswire (US)RXi Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment ConferenceNASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
 Showing the most relevant articles for your search:NASDAQ:RXII

Your Recent History

LSE
PANR
Pantheon Resources
LSE
PRIM
Primorus Investments
LSE
PFC
Petrofac
LSE
PHNX
Phoenix
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved